Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Current Deferred Revenue (2023 - 2025)

Historic Current Deferred Revenue for bioAffinity Technologies (BIAF) over the last 3 years, with Q3 2025 value amounting to $37915.0.

  • bioAffinity Technologies' Current Deferred Revenue rose 5536.39% to $37915.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $37915.0, marking a year-over-year increase of 5536.39%. This contributed to the annual value of $24404.0 for FY2024, which is 2617.82% down from last year.
  • As of Q3 2025, bioAffinity Technologies' Current Deferred Revenue stood at $37915.0, which was up 5536.39% from $24404.0 recorded in Q2 2025.
  • bioAffinity Technologies' 5-year Current Deferred Revenue high stood at $43000.0 for Q2 2023, and its period low was $24404.0 during Q3 2024.
  • Over the past 3 years, bioAffinity Technologies' median Current Deferred Revenue value was $28154.5 (recorded in 2024), while the average stood at $30614.8.
  • In the last 5 years, bioAffinity Technologies' Current Deferred Revenue tumbled by 3922.09% in 2024 and then skyrocketed by 5536.39% in 2025.
  • Over the past 3 years, bioAffinity Technologies' Current Deferred Revenue (Quarter) stood at $33058.0 in 2023, then dropped by 26.18% to $24404.0 in 2024, then surged by 55.36% to $37915.0 in 2025.
  • Its Current Deferred Revenue was $37915.0 in Q3 2025, compared to $24404.0 in Q2 2025 and $24404.0 in Q1 2025.